| Bioanalytical solutions and immunogenicity challenges of species-matched antibodies in preclinical studies while investigating protein-loaded long-acting intravitreal delivery … K Loyet, H Hernandez-Barry, K Barrett, M Maia, Y Liu, H Rafidi, ... Investigative Ophthalmology & Visual Science 65 (7), 3785-3785, 2024 | | 2024 |
| Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors J Grogan, RJ Johnston, B Irving, J Hackney, X Yu, D Eaton, K Bowles, ... US Patent App. 18/334,531, 2024 | | 2024 |
| Anti-interleukin-33 antibodies and uses thereof GR Nakamura, D Seshasayee, MVL Campagne, W Tiffany, J Wu, ... US Patent App. 18/364,185, 2024 | | 2024 |
| OPEN ACCESS EDITED BY RL Heise, NT Awatade, CM Magin, RE Hynds, T Hughes, KK Dijkstra, ... Innovative 3D models for Understanding Mechanisms underlying Lung Diseases …, 2024 | | 2024 |
| HPK1 citron homology domain regulates phosphorylation of SLP76 and modulates kinase domain interaction dynamics AS Chitre, P Wu, BT Walters, X Wang, A Bouyssou, X Du, I Lehoux, ... Nature Communications 15, 2024 | | 2024 |
| Structural basis of antibody inhibition and chemokine activation of the human CC chemokine receptor 8 D Sun, Y Sun, E Janezic, T Zhou, M Johnson, C Azumaya, S Noreng, ... Nature Communications 14 (1), 7940, 2023 | 6 | 2023 |
| OPEN ACCESS EDITED BY JE Pease, G Fonseca-Camarillo, NS Zubirán, MCD Sadik, C Deng, ... Progress and challenges with therapeutic targeting of chemokine receptors, 2023 | | 2023 |
| A novel, label‐free, pre‐equilibrium assay to determine the association and dissociation rate constants of therapeutic antibodies on living cells EM Janezic, A Doan, E Mai, DD Bravo, J Wang, HS Kim, C Spiess, ... British Journal of Pharmacology, 2023 | | 2023 |
| Anti-interleukin-33 antibodies and uses thereof GR Nakamura, D Seshasayee, MVL Campagne, W Tiffany, J Wu, ... US Patent 11,760,797, 2023 | | 2023 |
| Systematic pharmacological analysis of agonistic and antagonistic fibroblast growth factor receptor 1 MAbs reveals a similar unique mode of action J Chan, J Chan, L Shao, SS Stawicki, VC Pham, RW Akita, M Hafner, ... Journal of Biological Chemistry 299 (1), 2023 | | 2023 |
| Antibody targeting of E3 ubiquitin ligases for receptor degradation H Marei, WTK Tsai, YS Kee, K Ruiz, J He, C Cox, T Sun, S Penikalapati, ... Nature 610 (7930), 182-189, 2022 | 87 | 2022 |
| Generation of a Porcine Antibody Fab Fragment Using Protein Engineering to Facilitate the Evaluation of Ocular Sustained Delivery Technology RF Kelley, DB Tesar, Y Wang, NJ Agard, PG Holder, J Chan, ... Molecular Pharmaceutics 19 (5), 1540-1547, 2022 | | 2022 |
| Structural basis for HCMV Pentamer receptor recognition and antibody neutralization M Kschonsak, MC Johnson, R Schelling, EM Green, L Rougé, H Ho, ... Science advances 8 (10), eabm2536, 2022 | 20 | 2022 |
| Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses KL Banta, X Xu, AS Chitre, A Au-Yeung, C Takahashi, WE O’Gorman, ... Immunity 55 (3), 512-526. e9, 2022 | 169 | 2022 |
| novel method to produce synthetic murine CXCL10 for efficient screening of functional variants (vol 116, 105376, 2021) J Decalf, J Tom, E Mai, H Hernandez-Barry, CL Noland, BS Vollmar, A Li, ... BIOORGANIC CHEMISTRY 120, 2022 | | 2022 |
| Corrigendum to" A novel method to produce synthetic murine CXCL10 for efficient screening of functional variants"[Bioorg. Chem. 116 (2021) 105376] J Decalf, J Tom, E Mai, H Hernandez-Barry, CL Noland, BS Vollmar, A Li, ... Bioorganic chemistry 120, 105655, 2022 | | 2022 |
| Development of an ultra-sensitive human IL-33 biomarker assay for age-related macular degeneration and asthma drug development E Mai, J Chan, L Goon, BK Ego, J Bevers, T Wong, M Wong, R Corpuz, ... Journal of Translational Medicine 19, 1-15, 2021 | 3 | 2021 |
| Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors J Grogan, RJ Johnston, B Irving, J Hackney, X Yu, D Eaton, K Bowles, ... US Patent App. 17/367,094, 2021 | | 2021 |
| A novel method to produce synthetic murine CXCL10 for efficient screening of functional variants J Decalf, J Tom, E Mai, H Hernandez-Barry, CL Noland, BS Vollmar, A Li, ... Bioorganic Chemistry 116, 105376, 2021 | 2 | 2021 |
| Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors J Grogan, RJ Johnston, B Irving, J Hackney, X Yu, D Eaton, K Bowles, ... US Patent App. 17/367,133, 2021 | | 2021 |